Policy Issues In The Clinical Development And Use Of Immunotherapy For Cancer Treatment Proceedings Of A Workshop 1st Edition And Medicine Engineering National Academies Of Sciences Health And Medicine Division Board On Health Care Services National Cancer Policy Forum Sharyl J Nass Margie Patlak Kimberly Maxfield Erin Balogh by And Medicine Engineering National Academies Of Sciences; Health And Medicine Division; Board On Health Care Services; National Cancer Policy Forum; Sharyl J. Nass; Margie Patlak; Kimberly Maxfield; Erin Balogh 9780309442336, 0309442338 instant download after payment.

Immunotherapy is a form of cancer therapy that harnesses the body's immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop.